Clonal evolutionary analysis during HER2 blockade in HER2-positive inflammatory breast cancer: a phase II open-label clinical trial of afatinib +/- vinorelbineMore about Open Access at the Crick
Authors listGerald Goh Ramona Schmid Kelly Guiver Wichit Arpornwirat Imjai Chitapanarux Vinod Ganju Seock-Ah Im Sung-Bae Kim Arunee Dechaphunkul Jedzada Maneechavakajorn Neil Spector Thomas Yau Mehdi Afrit Slim Ben Ahmed Stephen R Johnston Neil Gibson Martina Uttenreuther-Fischer Javier Herrero Charles Swanton
Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer associated with HER2 amplification, with high risk of metastasis and an estimated median survival of 2.9 y. We performed an open-label, single-arm phase II clinical trial (ClinicalTrials.gov NCT01325428) to investigate the efficacy and safety of afatinib, an irreversible ErbB family inhibitor, alone and in combination with vinorelbine in patients with HER2-positive IBC. This trial included prospectively planned exome analysis before and after afatinib monotherapy.
Journal PLOS Medicine
Issue number 12